Adolescents
Demand insights for uptake of TB vaccine
Summarize the major swing factors that would determine countries’ preference and effectively drive the uptake of a TB vaccine in terms of the date of introduction and the scale of catch-up campaign to reach the steady state
TB case-finding in the context of future vaccines
Scenarios for future TB vaccines’ characteristics within which the value and cost-effectiveness of present-day interventions can be explored
Population-level health and economic impacts of introducing Vaccae vaccination in China: a modelling study
modelling the population-level health and economic impacts of introducing Vaccae vaccination to inform policy-makers in China
Is neglect of self-clearance biasing TB vaccine impact estimates?
exploring the inclusion of self-clearance in models of tuberculosis affects the estimates of vaccine impact in China and India
Bridging the gap: evaluating high TB burden country data needs to support the potential introduction of TB vaccines for adolescents and adults: a workshop report
A workshop to asked high TB burden country experts about what epidemiological, impact, feasibility and acceptability data they anticipated they would need to guide TB vaccine introduction.
Estimating the potential public health value of BCG revaccination
Using previously calibrated models for India and South Africa, we simulated BCG revaccination assuming 45% prevention-of-infection efficacy, and we evaluated scenarios varying additional prevention-of-disease efficacy between +50% (reducing risk) and −50% (increasing risk).
Meeting the 2030 End TB goals in the wake of COVID-19: a modelling study of countries in the USAID TB portfolio.
From 2023 onwards we modelled a combination of interventions acting at different stages of the care cascade, including improved diagnostics; reducing the patient care seeking delay; and the rollout of a disease-preventing vaccine from 2025 onwards.
Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine
Using mathematical models, we seek to estimate the potential impact of a post-exposure TB vaccine, having 50% efficacy in reducing active disease, on global rifampicin-resistant (RR-) TB burden.
An investment case for new tuberculosis vaccines
This document summarizes the results of the WHO-commissioned full value proposition for new TB vaccines. It is for use by national and global decision-makers involved in vaccine development and implementation.